GET DAILY SIGNALSGinkgo Bioworks (DNA) Advances +24.6% Over 30 Days on Partnership Momentum
Key Takeaways
- Ginkgo Bioworks (DNA) advanced roughly 24.6% over the last 30 days, from a closing price near $10.46 on September 28 to about $13.03 in late October.
- The move was led by a mid-September partnership with Eli Lilly to supply discovery data-generation services for AI-driven drug discovery.
- The stock is also up about 69% over the last three months, after touching an intraday high above $18 in early October before pulling back.
- Government-linked lab infrastructure announcements, including the National Science Foundation's X-Labs program, added further momentum.
- Analysts lifted price targets, but fundamentals remain challenged, with second-quarter revenue of roughly $20.2 million and an operating loss near $58.5 million.
- The rally remains volatile and driven heavily by AI and automation sentiment rather than confirmed revenue growth.
Company Snapshot: Ginkgo Bioworks (DNA)
Ginkgo Bioworks Holdings, Inc. is a Boston-based synthetic biology company that programs cells for applications across pharmaceuticals, agriculture, food, and industrial chemicals. Its platform combines automated laboratory infrastructure, software, and large-scale biological datasets to help partners design and test engineered organisms. Through offerings such as Ginkgo Automation, its Nebula autonomous laboratory, and Ginkgo Datapoints, the company provides R&D and data-generation services to biopharma and other customers.
Investors follow DNA for its exposure to AI-enabled drug discovery, laboratory automation, and government-backed biosecurity initiatives. However, the company has yet to translate its partnerships into consistent profitability, and revenue has declined during its ongoing restructuring. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30 Days Versus the Quarter
Over the last 30 days, DNA climbed about 24.6%, moving from a closing price of approximately $10.46 on September 28 to around $13.03 in late October. The advance was uneven: the stock surged to an intraday high above $18 on October 6 before giving back a substantial portion of those gains, then stabilized in the $10-to-$13 range.
The broader three-month trend is even stronger. From a close near $7.70 in late July, the shares gained roughly 69%, reflecting a sharp re-rating that began after the company's Eli Lilly partnership was announced and accelerated through September and October. The quarterly pattern shows a stock that trended lower through August before reversing sharply on AI and automation headlines.
Key Drivers Behind the 30-Day Move
The primary catalyst was the September announcement that Ginkgo Datapoints reached an agreement with Eli Lilly's TuneLab to provide discovery data-generation services, including small-molecule and antibody developability testing, for AI and machine-learning-driven drug discovery. The news triggered a sustained rally and a sharp increase in trading volume.
Additional developments reinforced the move. In early October, Ginkgo said it would provide in-kind access to its autonomous Boston laboratory for the National Science Foundation's $1.5 billion X-Labs program, announced with the White House Office of Science and Technology Policy. The company also integrated Araceli Biosciences' high-content imaging system into its Nebula lab and received a subcontract of up to $17.5 million under an ARPA-H program focused on automated RNA drug manufacturing.
Wall Street responded positively. TD Cowen raised its price target on DNA to $11 from $9 while maintaining a Hold rating, citing what it described as one of the strongest quarters in two decades for the life science tools sector, supported by biotech funding and AI demand. These headlines outweighed ongoing concerns about declining revenue and lack of profitability, though volatility remained elevated throughout the period.
Drivers of the Broader Quarterly Advance
The three-month advance was shaped by a broader pivot toward AI and automation narratives. After a weak summer, during which the stock drifted toward the mid-$6 range, investor sentiment improved as Ginkgo emphasized its autonomous lab infrastructure, data services, and AI-linked partnerships. The Eli Lilly agreement became the clearest validation of that strategy and re-focused attention on the company's ability to monetize its datasets.
Second-quarter results, reported in the summer, showed revenue of roughly $20.2 million, down from $39.1 million a year earlier, with an operating loss near $58.5 million. While cost reductions were noted favorably by some analysts, the quarter underscored that revenue execution had not yet caught up with the stock's valuation. Government contract wins and sector-wide optimism in life science tools provided additional support, but the rally's durability remains tied to future financial results.
What to Watch Next for DNA
The next major checkpoint is Ginkgo Bioworks' quarterly earnings and guidance update, which will test whether recent AI and automation enthusiasm translates into measurable revenue progress. Investors should monitor revenue recognition, cash burn, and any updated profitability targets, given that the company remains unprofitable.
Additional factors to watch include the execution of the Eli Lilly partnership, further government contract awards, analyst rating and price-target revisions, and the broader trajectory of biotech funding and AI-linked demand in life science tools. Competition, slower-than-expected adoption of automated lab services, and continued insider selling represent key risks that could weigh on sentiment if momentum fades.
Using Tickeron’s Trending AI Robots for Strategy Ideas
One resource I turn to when evaluating systematic approaches is Tickeron’s Trending AI Robots page. It highlights a selection of automated trading bots from a wider universe of strategies, focusing on those showing strong recent performance across different timeframes and market conditions. This can provide a practical complement to fundamental analysis when considering stocks like DNA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 69 cases where DNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on DNA as a result. In 79 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The 10-day moving average for DNA crossed bullishly above the 50-day moving average on September 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Following a +32.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 91 of 109 cases where DNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 22 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 46 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
DNA broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.134) is normal, around the industry mean (3.151). P/E Ratio (-2.664) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement